The role of nanotechnology in the treatment of viral infections

Infectious diseases are the leading cause of mortality worldwide, with viruses in particular making global impact on healthcare and socioeconomic development. In addition, the rapid development of drug resistance to currently available therapies and adverse side effects due to prolonged use is a serious public health concern. The development of novel treatment strategies is therefore required. The interaction of nanostructures with microorganisms is fast-revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles offer unique physical properties that have associated benefits for drug delivery. These are predominantly due to the particle size (which affects bioavailability and circulation time), large surface area to volume ratio (enhanced solubility compared to larger particles), tunable surface charge of the particle with the possibility of encapsulation, and large drug payloads that can be accommodated. These properties, which are unlike bulk materials of the same compositions, make nanoparticulate drug delivery systems ideal candidates to explore in order to achieve and/or improve therapeutic effects. This review presents a broad overview of the application of nanosized materials for the treatment of common viral infections.

[1]  Arti Vashist,et al.  Electrochemical Biosensors for Early Stage Zika Diagnostics. , 2017, Trends in biotechnology.

[2]  M. Gagliardi Biomimetic and bioinspired nanoparticles for targeted drug delivery. , 2017, Therapeutic delivery.

[3]  F. Kashanchi,et al.  Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection , 2017, Journal of Neuroimmune Pharmacology.

[4]  L. Chonco,et al.  Potential inhibition of HIV-1 encapsidation by oligoribonucleotide–dendrimer nanoparticle complexes , 2017, International journal of nanomedicine.

[5]  Yu-Cheng Su,et al.  Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. , 2016, Analytical chemistry.

[6]  M. Nair,et al.  Recent trends on hydrogel based drug delivery systems for infectious diseases. , 2016, Biomaterials science.

[7]  T. Govender,et al.  Intracellular localization of gold nanoparticles with targeted delivery in MT-4 lymphocytes , 2016 .

[8]  M. Yuen,et al.  New pharmacological approaches to a functional cure of hepatitis B , 2016, Clinical liver disease.

[9]  K. S. Rajan,et al.  Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. , 2016, Colloids and surfaces. B, Biointerfaces.

[10]  H. Xia,et al.  Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways. , 2016, ACS applied materials & interfaces.

[11]  Ajeet Kaushik,et al.  Advancements in nano-enabled therapeutics for neuroHIV management , 2016, International journal of nanomedicine.

[12]  Seung‐Woo Cho,et al.  Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[13]  A. Kaushik,et al.  Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. , 2016, Advanced drug delivery reviews.

[14]  Y. Liu,et al.  Role of nanotechnology in HIV/AIDS vaccine development. , 2016, Advanced drug delivery reviews.

[15]  C. Lubich,et al.  The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? , 2016, Pharmaceutical Research.

[16]  Vikas Sharma,et al.  Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies. , 2016, Protein expression and purification.

[17]  M. Nair,et al.  Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers , 2016, Scientific Reports.

[18]  Pu Li,et al.  Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C , 2016, Scientific Reports.

[19]  Bin Zhou,et al.  Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. , 2016, Vaccine.

[20]  Xuesi Chen,et al.  Production and clinical development of nanoparticles for gene delivery , 2016, Molecular therapy. Methods & clinical development.

[21]  P. Horby,et al.  Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial , 2016, PLoS medicine.

[22]  L. Gostin,et al.  The Emerging Zika Pandemic: Enhancing Preparedness. , 2016, JAMA.

[23]  J. M. Lanao,et al.  Current applications of nanoparticles in infectious diseases. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[24]  S. Kent,et al.  Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination , 2016, Expert review of vaccines.

[25]  A. Gulland Zika virus is a global public health emergency, declares WHO , 2016, BMJ : British Medical Journal.

[26]  T. Govender,et al.  Binding Free Energy Calculations of Nine FDA‐approved Protease Inhibitors Against HIV‐1 Subtype C I36T↑T Containing 100 Amino Acids Per Monomer , 2016, Chemical biology & drug design.

[27]  R. Gómez,et al.  Nanotechnology as a New Therapeutic Approach to Prevent the HIV-Infection of Treg Cells , 2016, PloS one.

[28]  G. Borchard,et al.  Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice. , 2016, Molecular pharmaceutics.

[29]  V. Zarytova,et al.  Nanoparticle-Mediated Nonviral DNA Delivery for Effective Inhibition of Influenza a Viruses in Cells , 2016, IEEE Transactions on Nanotechnology.

[30]  Catharina de Lange Davies,et al.  Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles , 2016, Journal of Nanobiotechnology.

[31]  Mahesh Attimarad,et al.  Formulation and evaluation of nano based drug delivery system for the buccal delivery of acyclovir. , 2015, Colloids and surfaces. B, Biointerfaces.

[32]  S. Manzoor,et al.  Hepatitis B virus therapy: What's the future holding for us? , 2015, World journal of gastroenterology.

[33]  Yonghou Jiang,et al.  Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission. , 2015, Molecular pharmaceutics.

[34]  S. Adesina,et al.  Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy. , 2015, Molecular pharmaceutics.

[35]  A. Ghaemi,et al.  Chitosan nanoparticles as a potential nonviral gene delivery for HPV-16 E7 into mammalian cells , 2015, Artificial cells, nanomedicine, and biotechnology.

[36]  A. Chávez-Reyes,et al.  Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[37]  Liju Yang,et al.  Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles , 2015, PloS one.

[38]  O. Abián,et al.  Shell Cross-Linked Polymeric Micelles as Camptothecin Nanocarriers for Anti-HCV Therapy. , 2015, Macromolecular bioscience.

[39]  R. Boukherroub,et al.  Nanostructures for the Inhibition of Viral Infections , 2015, Molecules.

[40]  Y. Chai,et al.  An amplified electrochemical immunosensor based on in situ-produced 1-naphthol as electroactive substance and graphene oxide and Pt nanoparticles functionalized CeO2 nanocomposites as signal enhancer. , 2015, Biosensors & bioelectronics.

[41]  A. Bolhassani,et al.  MPG-based nanoparticle: An efficient delivery system for enhancing the potency of DNA vaccine expressing HPV16E7. , 2015, Vaccine.

[42]  S. Nekhai,et al.  Activation of HIV-1 with Nanoparticle-Packaged Small-Molecule Protein Phosphatase-1-Targeting Compound , 2015, Scientia pharmaceutica.

[43]  M. D. Hussain,et al.  Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[44]  V. Lohmann,et al.  Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication , 2015, Hepatology.

[45]  N. Snead,et al.  Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates , 2015, Nature.

[46]  V. Valcour,et al.  CNS reservoirs for HIV: implications for eradication , 2015, Journal of virus eradication.

[47]  Amit Jain,et al.  Nanotechnology: A magic bullet for HIV AIDS treatment , 2015, Artificial cells, nanomedicine, and biotechnology.

[48]  M. Nair,et al.  Sustained-release nanoART formulation for the treatment of neuroAIDS , 2015, International journal of nanomedicine.

[49]  Seung Jun Oh,et al.  Integration of reverse transcriptase loop-mediated isothermal amplification with an immunochromatographic strip on a centrifugal microdevice for influenza A virus identification. , 2015, Lab on a chip.

[50]  Q. Wang,et al.  A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma. , 2014, Current pharmaceutical design.

[51]  I. Chaiken,et al.  Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation* , 2014, The Journal of Biological Chemistry.

[52]  D. Hazuda,et al.  Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[53]  Hansoo Park,et al.  Nanotechnology for diagnosis and treatment of infectious diseases. , 2014, Journal of nanoscience and nanotechnology.

[54]  Joo Yeon Park,et al.  Nanotechnology and vaccine development , 2014 .

[55]  Benjamin Michen,et al.  Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages , 2014, Beilstein journal of nanotechnology.

[56]  M. Tafaghodi,et al.  Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin , 2014, Iranian journal of basic medical sciences.

[57]  Piotr Orlowski,et al.  Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in Herpes Simplex Virus Type 2 Infection , 2014, PloS one.

[58]  Yanfei Tao,et al.  Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[59]  K. Chatterjee,et al.  Core/shell nanoparticles in biomedical applications. , 2014, Advances in colloid and interface science.

[60]  S. Penadés,et al.  Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs , 2014, Beilstein journal of organic chemistry.

[61]  M. Radomski,et al.  Pegylation increases platelet biocompatibility of gold nanoparticles. , 2014, Journal of biomedical nanotechnology.

[62]  T. Ebensen,et al.  A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung. , 2014, Vaccine.

[63]  Ji-Ho Park,et al.  Surface chemistry of gold nanoparticles mediates their exocytosis in macrophages. , 2014, ACS nano.

[64]  Maria João Gomes,et al.  Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system , 2014, International journal of nanomedicine.

[65]  E. Petricoin,et al.  The use of Nanotrap particles for biodefense and emerging infectious disease diagnostics , 2014, Pathogens and disease.

[66]  X. Guan,et al.  Inhibition effect of silver nanoparticles on herpes simplex virus 2. , 2014, Genetics and molecular research : GMR.

[67]  Dik van de Meent,et al.  Cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type , 2014, Environmental toxicology and chemistry.

[68]  M. Leal,et al.  HIV Infection Deregulates the Balance Between Regulatory T Cells and IL-2–Producing CD4 T Cells by Decreasing the Expression of the IL-2 Receptor in Treg , 2014, Journal of acquired immune deficiency syndromes.

[69]  C. Sabliov,et al.  Nanodelivery of bioactive components for food applications: types of delivery systems, properties, and their effect on ADME profiles and toxicity of nanoparticles. , 2014, Annual review of food science and technology.

[70]  Harvinder S Gill,et al.  Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. , 2014, Nanomedicine.

[71]  L. Lee,et al.  Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs , 2014, International journal of nanomedicine.

[72]  K. Yamanishi,et al.  Chitosan Nanoparticle Encapsulated Hemagglutinin-Split Influenza Virus Mucosal Vaccine , 2013, AAPS PharmSciTech.

[73]  Mahendra Rai,et al.  Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: A review , 2013, Applied Microbiology and Biotechnology.

[74]  J. Lisziewicz,et al.  Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial , 2013, Journal of acquired immune deficiency syndromes.

[75]  S. Choudhary,et al.  Development and In Vitro-In Vivo Evaluation of Oral Drug Delivery System of Acyclovir Loaded PLGA nanoparticles. , 2013 .

[76]  A. Ingle,et al.  Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3 , 2013, International journal of nanomedicine.

[77]  Andrew J Thorley,et al.  New perspectives in nanomedicine. , 2013, Pharmacology & therapeutics.

[78]  C. Jeynes,et al.  Measuring and modelling cell-to-cell variation in uptake of gold nanoparticles. , 2013, The Analyst.

[79]  J. Majoral,et al.  Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview , 2013 .

[80]  Sanjiv Sonkaria,et al.  Targeting C-type lectin receptors with multivalent carbohydrate ligands. , 2013, Advanced drug delivery reviews.

[81]  O. Abián,et al.  Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus , 2013, PloS one.

[82]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[83]  G. Renukaradhya,et al.  PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs , 2013, Veterinary Microbiology.

[84]  J. DeSimone,et al.  Development of a nanoparticle-based influenza vaccine using the PRINT technology. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[85]  K. Woodrow,et al.  Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis , 2013, PloS one.

[86]  M. Kheiri,et al.  Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization , 2013, Archives of pharmacal research.

[87]  J. Reineke,et al.  Quantitative detection of PLGA nanoparticle degradation in tissues following intravenous administration. , 2013, Molecular pharmaceutics.

[88]  Anthony E. Gregory,et al.  Vaccine delivery using nanoparticles , 2013, Front. Cell. Infect. Microbiol..

[89]  Michael Riediker,et al.  Therapeutic nanoparticles in clinics and under clinical evaluation. , 2013, Nanomedicine.

[90]  P. Gide,et al.  Enhancement of Transdermal Penetration and Bioavailability of Poorly Soluble Acyclovir Using Solid Lipid Nanoparticles Incorporated in Gel Cream , 2013, Indian journal of pharmaceutical sciences.

[91]  Linda Pastero,et al.  Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy. , 2013, International journal of pharmaceutics.

[92]  H. Ploegh,et al.  Sialylneolacto-N-tetraose c (LSTc)-bearing Liposomal Decoys Capture Influenza A Virus* , 2013, The Journal of Biological Chemistry.

[93]  R. Adelung,et al.  Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection. , 2012, Antiviral research.

[94]  K. Kaur,et al.  A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. , 2012, Vaccine.

[95]  Kwangmeyung Kim,et al.  Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection. , 2012, ACS nano.

[96]  Pascal Richette,et al.  Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents , 2012, Expert opinion on drug delivery.

[97]  W. Law,et al.  Anti-HIV-1 nanotherapeutics: promises and challenges for the future , 2012, International journal of nanomedicine.

[98]  S. Barik New treatments for influenza , 2012, BMC Medicine.

[99]  M. Hua,et al.  Potential of magnetic nanoparticles for targeted drug delivery. , 2012, Nanotechnology, science and applications.

[100]  Jill M. Steinbach,et al.  Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[101]  R. Sarid,et al.  Surface-modified protein nanospheres as potential antiviral agents. , 2012, Chemical communications.

[102]  Nicolas Bertrand,et al.  The journey of a drug-carrier in the body: an anatomo-physiological perspective. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[103]  Soon Hye Yang,et al.  Nanoparticle-based artificial RNA silencing machinery for antiviral therapy , 2012, Proceedings of the National Academy of Sciences.

[104]  Xi Jiang,et al.  Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. , 2012, Nanomedicine.

[105]  Benjamin C. Tang,et al.  Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus , 2012, Science Translational Medicine.

[106]  N. Kuntworbe,et al.  Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management , 2012 .

[107]  S. Paria,et al.  Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. , 2012, Chemical reviews.

[108]  Glenn E. M. Maguire,et al.  Nanotechnology and the Treatment of HIV Infection , 2012, Viruses.

[109]  Xingyu Jiang,et al.  The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. , 2012, Biomaterials.

[110]  J. Hubbell,et al.  Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages , 2012, International journal of nanomedicine.

[111]  R. Tilley,et al.  Synthesis and Stability of Highly Crystalline and Stable Iron/Iron Oxide Core/Shell Nanoparticles for Biomedical Applications , 2012 .

[112]  Weipeng Cao,et al.  Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. , 2012, Biomaterials.

[113]  R. Kaul,et al.  Measurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% StarPharma LTD 7013 Gel (VivaGel) to Assess Expanded Safety , 2012, Journal of acquired immune deficiency syndromes.

[114]  Young Jik Kwon,et al.  "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[115]  John T Elliott,et al.  Stable nanoparticle aggregates/agglomerates of different sizes and the effect of their size on hemolytic cytotoxicity , 2011, Nanotoxicology.

[116]  E. R. de Celis,et al.  Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[117]  V. Patravale,et al.  AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. , 2011, Journal of biomedical nanotechnology.

[118]  J. Burnett,et al.  Current progress of siRNA/shRNA therapeutics in clinical trials , 2011, Biotechnology journal.

[119]  M. Peng,et al.  Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. , 2011, International journal of pharmaceutics.

[120]  H. H. Lara,et al.  Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds , 2011, Journal of nanobiotechnology.

[121]  Sanyog Jain,et al.  Enhanced dermal delivery of acyclovir using solid lipid nanoparticles , 2011, Drug Delivery and Translational Research.

[122]  Yang Liu,et al.  In vivo delivery of RNAi with lipid-based nanoparticles. , 2011, Annual review of biomedical engineering.

[123]  Warren C W Chan,et al.  Effect of gold nanoparticle aggregation on cell uptake and toxicity. , 2011, ACS nano.

[124]  A. Baas,et al.  FDA-approved poly(ethylene glycol)–protein conjugate drugs , 2011 .

[125]  B. Richardson,et al.  Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004) , 2011, AIDS.

[126]  Rainer H Müller,et al.  State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[127]  P. Hammond,et al.  Controlling in vivo stability and biodistribution in electrostatically assembled nanoparticles for systemic delivery. , 2011, Nano letters.

[128]  M. Marsden,et al.  Activation of Latent HIV Using Drug-Loaded Nanoparticles , 2011, PloS one.

[129]  Lev Dykman,et al.  Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. , 2011, Chemical Society reviews.

[130]  M. Zamora,et al.  RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. , 2011, American journal of respiratory and critical care medicine.

[131]  Joelle M. Brown,et al.  A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days , 2011, PloS one.

[132]  P. Eastman Progress Being Made on Potential of Microbicides to Prevent Genital HPV Infection , 2010 .

[133]  Si-Shen Feng,et al.  Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. , 2010, International journal of pharmaceutics.

[134]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[135]  D. Chiappetta,et al.  Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. , 2010, Colloids and surfaces. B, Biointerfaces.

[136]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[137]  L. Rohan,et al.  Progress in antiretroviral drug delivery using nanotechnology , 2010, International journal of nanomedicine.

[138]  Jianqing Gao,et al.  Potential neurotoxicity of nanoparticles. , 2010, International journal of pharmaceutics.

[139]  Xinying Wu,et al.  Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. , 2010, Biomaterials.

[140]  E. Goldys,et al.  Non-specific cellular uptake of surface-functionalized quantum dots , 2010, Nanotechnology.

[141]  H. Sharma,et al.  Conference scene: Nanoneuroprotection and nanoneurotoxicity: recent progress and future perspectives. , 2010, Nanomedicine.

[142]  Joshua C. Johnson,et al.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.

[143]  P. Couvreur,et al.  Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. , 2010, Bioorganic & medicinal chemistry letters.

[144]  Rob Lambkin-Williams,et al.  A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus , 2010, Proceedings of the National Academy of Sciences.

[145]  Chad A. Mirkin,et al.  Gold nanoparticles for biology and medicine. , 2010, Angewandte Chemie.

[146]  Rasesh Y Parikh,et al.  Biological synthesis of metallic nanoparticles. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[147]  N. K. Jain,et al.  Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. , 2010, Advanced drug delivery reviews.

[148]  V. Mosqueira,et al.  Nanotechnology applied to the treatment of malaria. , 2010, Advanced drug delivery reviews.

[149]  R. Hurt,et al.  Ion release kinetics and particle persistence in aqueous nano-silver colloids. , 2010, Environmental science & technology.

[150]  R. Langer,et al.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. , 2010, Nanomedicine.

[151]  C. Rodríguez-Padilla,et al.  Mode of antiviral action of silver nanoparticles against HIV-1 , 2010, Journal of nanobiotechnology.

[152]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[153]  J. Blackard,et al.  Human Regulatory T Cells Are Targets for Human Immunodeficiency Virus (HIV) Infection, and Their Susceptibility Differs Depending on the HIV Type 1 Strain , 2009, Journal of Virology.

[154]  P. Hamal,et al.  Antifungal activity of silver nanoparticles against Candida spp. , 2009, Biomaterials.

[155]  T. Shibamoto,et al.  Effect of nanoparticles on the male reproductive system of mice. , 2009, International journal of andrology.

[156]  Nelson A. Ochekpe,et al.  Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery , 2009 .

[157]  C. Herzog,et al.  Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. , 2009, Vaccine.

[158]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[159]  Gabriele Neumann,et al.  Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.

[160]  Rajesh Singh,et al.  Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.

[161]  K. Fukuzaki,et al.  Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer1 , 2009, The Journal of Immunology.

[162]  J. Nauta,et al.  Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity. , 2009, Vaccine.

[163]  A. Bourinbaiar,et al.  Clinical experience with therapeutic vaccines designed for patients with hepatitis. , 2009, Current pharmaceutical design.

[164]  M. Stevanović,et al.  Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins , 2009 .

[165]  Yvonne Perrie,et al.  Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. , 2008, International journal of pharmaceutics.

[166]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: aciclovir. , 2008, Journal of pharmaceutical sciences.

[167]  M. Jafelicci,et al.  Iron Oxide Versus Fe $_{55}$ Pt $_{45}$ /Fe $_{3}$ O $_{4}$ : Improved Magnetic Properties of Core/Shell Nanoparticles for Biomedical Applications , 2008 .

[168]  Qingxiu Wang,et al.  Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity. , 2008, Toxicology and applied pharmacology.

[169]  P. Bovier Epaxal®: a virosomal vaccine to prevent hepatitis A infection , 2008, Expert review of vaccines.

[170]  Menachem Elimelech,et al.  Aggregation kinetics of multiwalled carbon nanotubes in aquatic systems: measurements and environmental implications. , 2008, Environmental science & technology.

[171]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[172]  Nuria Sanvicens,et al.  Multifunctional nanoparticles--properties and prospects for their use in human medicine. , 2008, Trends in biotechnology.

[173]  Samir Mitragotri,et al.  Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[174]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[175]  John Crittenden,et al.  Photocatalytic inactivation of viruses using titanium dioxide nanoparticles and low-pressure UV light , 2008, Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering.

[176]  W. D. de Jong,et al.  Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.

[177]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[178]  Christian Melander,et al.  Inhibition of HIV fusion with multivalent gold nanoparticles. , 2008, Journal of the American Chemical Society.

[179]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[180]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[181]  E. Poeschla,et al.  Integrase, LEDGF/p75 and HIV replication , 2008, Cellular and Molecular Life Sciences.

[182]  L. Stanberry,et al.  VivaGel™ (SPL7013 Gel): A candidate dendrimer – microbicide for the prevention of HIV and HSV infection , 2007, International journal of nanomedicine.

[183]  W. Chan,et al.  Nanotoxicity: the growing need for in vivo study. , 2007, Current opinion in biotechnology.

[184]  T. Tatusova,et al.  The Influenza Virus Resource at the National Center for Biotechnology Information , 2007, Journal of Virology.

[185]  Y. Kuo,et al.  Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. , 2007, International journal of pharmaceutics.

[186]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[187]  Á. Delgado,et al.  Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications. , 2007, International journal of pharmaceutics.

[188]  E. Shusta,et al.  Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.

[189]  Kemin Wang,et al.  Preparation and antibacterial activity of Fe3O4@Ag nanoparticles , 2007 .

[190]  Shibo Jiang,et al.  Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide , 2007, Cell.

[191]  Mansoor M. Amiji,et al.  Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery , 2007, Pharmaceutical Research.

[192]  K. Letchford,et al.  A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[193]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[194]  Michael S. Goldberg,et al.  Nanostructured materials for applications in drug delivery and tissue engineering , 2007, Journal of biomaterials science. Polymer edition.

[195]  N. K. Jain,et al.  Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro , 2007, Journal of drug targeting.

[196]  Long Jiang,et al.  Influence of Generation 2–5 of PAMAM Dendrimer on the Inhibition of Tat Peptide/ TAR RNA Binding in HIV‐1 Transcription , 2006, Chemical biology & drug design.

[197]  N Toub,et al.  Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[198]  A. Bandyopadhyay,et al.  Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[199]  Christopher J. Destache,et al.  Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System , 2006, Journal of Neuroimmune Pharmacology.

[200]  Wolfgang J Parak,et al.  Laser-induced release of encapsulated materials inside living cells. , 2006, Angewandte Chemie.

[201]  P. Couvreur,et al.  Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.

[202]  J. Doorbar,et al.  Molecular biology of human papillomavirus infection and cervical cancer. , 2006, Clinical science.

[203]  T. Xia,et al.  Toxic Potential of Materials at the Nanolevel , 2006, Science.

[204]  Malcolm L. H. Green,et al.  Complement activation and protein adsorption by carbon nanotubes. , 2006, Molecular immunology.

[205]  S. Cosgrove The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[206]  Gregory Gregoriadis,et al.  The ‘Co-Delivery’ Approach to Liposomal Vaccines: Application to the Development of influenza-A and hepatitis-B Vaccine Candidates , 2006, Journal of liposome research.

[207]  Anne-Marie Caminade,et al.  Characterization of dendrimers. , 2005, Advanced drug delivery reviews.

[208]  Tetsuya Osaka,et al.  THE STUDY OF ANTIMICROBIAL ACTIVITY AND PRESERVATIVE EFFECTS OF NANOSILVER INGREDIENT , 2005 .

[209]  W. Couet,et al.  Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 Mice , 2005, Pharmaceutical Research.

[210]  Claudia Fruijtier-Pölloth Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. , 2005, Toxicology.

[211]  C. Che,et al.  Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. , 2005, Chemical communications.

[212]  Michael S Saag,et al.  Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 , 2005, Nature Medicine.

[213]  M. Sjogren Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. , 2005, The American journal of medicine.

[214]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[215]  Andre F Palmer,et al.  Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. , 2005, Biomacromolecules.

[216]  R. Srinivasan,et al.  Is polyethylene glycol safe and effective for chronic constipation in children? , 2005, Archives of Disease in Childhood.

[217]  Andrea Scozzafava,et al.  Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. , 2005, Current pharmaceutical design.

[218]  Thomas Rades,et al.  Lipid based particulate formulations for the delivery of antigen , 2005, Immunology and cell biology.

[219]  C. Murphy,et al.  Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. , 2005, Small.

[220]  S. Akira,et al.  Involvement of Toll-like Receptor 3 in the Immune Response of Lung Epithelial Cells to Double-stranded RNA and Influenza A Virus* , 2005, Journal of Biological Chemistry.

[221]  Chad A. Mirkin,et al.  Nanobiotechnology :concepts, applications and perspectives , 2005 .

[222]  Steven F Dowdy,et al.  Cationic TAT peptide transduction domain enters cells by macropinocytosis. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[223]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[224]  A. Banerjee,et al.  Role of Nucleolin in Human Parainfluenza Virus Type 3 Infection of Human Lung Epithelial Cells , 2004, Journal of Virology.

[225]  Mark S. Sundrud,et al.  HIV Infection of Naturally Occurring and Genetically Reprogrammed Human Regulatory T-cells , 2004, PLoS biology.

[226]  Vincent M Rotello,et al.  Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. , 2004, Bioconjugate chemistry.

[227]  Stuart T. Nichol,et al.  Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral Load as a Predictor of Outcome , 2004, Journal of Virology.

[228]  G. Reinhardt,et al.  Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in healthy toddlers and children in Chile , 2004, Acta paediatrica.

[229]  R B Sim,et al.  Proteases of the complement system. , 2004, Biochemical Society transactions.

[230]  S. Sahoo,et al.  Nanotech approaches to drug delivery and imaging. , 2003, Drug discovery today.

[231]  Jayanth Panyam,et al.  Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[232]  Raoul Kopelman,et al.  Room-temperature preparation and characterization of poly (ethylene glycol)-coated silica nanoparticles for biomedical applications. , 2003, Journal of biomedical materials research. Part A.

[233]  J. Baker,et al.  Inactivation of Ebola virus with a surfactant nanoemulsion. , 2003, Acta tropica.

[234]  H. Fessi,et al.  Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis , 2003, Annals of tropical medicine and parasitology.

[235]  E. Vivés,et al.  TAT peptide internalization: seeking the mechanism of entry. , 2003, Current protein & peptide science.

[236]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[237]  R. Mischler,et al.  Inflexal V a trivalent virosome subunit influenza vaccine: production. , 2002, Vaccine.

[238]  Alexander V Kabanov,et al.  Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[239]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[240]  Bo Nilsson,et al.  C3 Adsorbed to a Polymer Surface Can Form an Initiating Alternative Pathway Convertase1 , 2002, The Journal of Immunology.

[241]  B. Murphy,et al.  Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. , 2002, Virology.

[242]  H. Klenk,et al.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections , 2002, Reviews in medical virology.

[243]  M. Garnett,et al.  Targeted drug conjugates: principles and progress. , 2001, Advanced drug delivery reviews.

[244]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[245]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[246]  M. Ghannoum,et al.  New targets and delivery systems for antifungal therapy. , 2000, Medical mycology.

[247]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[248]  R. Murray,et al.  Monolayer-protected cluster molecules. , 2000, Accounts of chemical research.

[249]  D. Cooper,et al.  HIV protease inhibitors , 1996, AIDS.

[250]  R. G. Freeman,et al.  Preparation and Characterization of Au Colloid Monolayers , 1995 .

[251]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[252]  L. Corey,et al.  Treatment of herpes simplex virus infections. , 1987, Clinics in laboratory medicine.

[253]  R. Reichman Herpes simplex virus infections , 1984, European Journal of Clinical Microbiology.

[254]  O. Laskin Clinical Pharmacokinetics of Acyclovir , 1983, Clinical pharmacokinetics.

[255]  byBrooke LaBranche,et al.  Gold nanoparticles in delivery applications ? , 2018 .

[256]  Tejabhiram Yadavalli,et al.  Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[257]  M. Swartz,et al.  A Polypropylene sulfide nanoparticle p24 vaccine promotes dendritic cell-mediated specific immune responses against HIV-1 , 2016 .

[258]  D. M.,et al.  Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. , 2016, The New England journal of medicine.

[259]  M. López-Quintela,et al.  Core-shell nanocatalysts obtained in reverse micelles: structural and kinetic aspects , 2015 .

[260]  Chun-Xia Zhao,et al.  Nanoparticle vaccines. , 2014, Vaccine.

[261]  V. Labhasetwar,et al.  Nanoparticles: cellular uptake and cytotoxicity. , 2014, Advances in experimental medicine and biology.

[262]  M. Joshi,et al.  Nanomedicines for treatment of viral diseases. , 2013, Critical reviews in therapeutic drug carrier systems.

[263]  R. Cavalli,et al.  Enhanced antiviral activity of acyclovir loaded into nanoparticles. , 2012, Methods in enzymology.

[264]  S. Mohapatra,et al.  Nanotechnology Applications to HIV Vaccines and Microbicides , 2012, Journal of Global Infectious Diseases.

[265]  Scott E McNeil,et al.  Unique benefits of nanotechnology to drug delivery and diagnostics. , 2011, Methods in molecular biology.

[266]  A. Denys [Antiviral drugs]. , 2011, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[267]  R. Bawa Nanopharmaceuticals: Nanopharmaceuticals , 2010 .

[268]  Marie-Pierre de Béthune,et al.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.

[269]  T. Cihlar,et al.  Current status and challenges of antiretroviral research and therapy. , 2010, Antiviral research.

[270]  T. Cihlar,et al.  Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. , 2010, Antiviral research.

[271]  Wen-chao Song,et al.  Complement and its role in innate and adaptive immune responses , 2010, Cell Research.

[272]  Frederick Hayden,et al.  Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[273]  Samir Mitragotri,et al.  Physical approaches to biomaterial design. , 2009, Nature materials.

[274]  M. Rai,et al.  Silver nanoparticles as a new generation of antimicrobials. , 2009, Biotechnology advances.

[275]  M. S. Muthu,et al.  Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. , 2009, Nanomedicine.

[276]  H. Fessi,et al.  olymer-based nanocapsules for drug delivery , 2009 .

[277]  Krishnakiran Medepalli,et al.  Advanced nanomaterials for biomedical applications , 2008 .

[278]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[279]  Samir Mitragotri,et al.  Shape Induced Inhibition of Phagocytosis of Polymer Particles , 2008, Pharmaceutical Research.

[280]  Hari Singh Nalwa,et al.  Handbook of nanostructured materials and nanotechnology , 2000 .

[281]  Dorothea Pfeiffer,et al.  Biosensoren: Grundlagen und Anwendungen , 1995 .

[282]  Mathias Brust,et al.  Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system , 1994 .

[283]  E. Åkerblom,et al.  Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. , 1984, International archives of allergy and applied immunology.

[284]  G. Frens Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions , 1973 .

[285]  J W DUGGAN,et al.  Herpes simplex virus. , 1961, Transactions of the Canadian Ophthalmological Society.

[286]  J. Hillier,et al.  A study of the nucleation and growth processes in the synthesis of colloidal gold , 1951 .